Loading organizations...
§ Private Profile · Heverlee, Vlaams-Brabant, Belgium
Biotechnology company developing a plug-and-play vaccine platform for preventive and therapeutic infectious diseases, focused on thermostability.
AstriVax is a clinical-stage biotechnology company based in Leuven, Belgium, that develops a proprietary plug-and-play platform technology for preventive and therapeutic vaccines against infectious diseases. The company utilizes thermostable technology to significantly reduce global cold chain storage requirements while advancing a clinical pipeline of immunotherapies targeting yellow fever, rabies, and hepatitis B. To commercialize its platform, the enterprise secured €30 million in seed funding from lead investors including V-Bio Ventures, Fund+, and Mérieux Equity Partners. The organization recently initiated first-in-human clinical trials simultaneously testing multiple vaccine assets across two Belgian sites, and it received a €2.5 million research grant to support its therapeutic pipeline. Operating as an independent corporate entity, the biotechnology firm AstriVax was officially founded in 2022 as an academic spin-off from KU Leuven by Hanne Callewaert, Johan Neyts, and Kai Dallmeier.
AstriVax has raised $35.8M across 3 funding rounds.
AstriVax has raised $35.8M in total across 3 funding rounds.
AstriVax has raised $35.8M in total across 3 funding rounds.
AstriVax's investors include VLAIO, Caroline Goddeeris, Shelley Margetson, Ackermans & van Haaren, BNP Paribas Fortis Private Equity, Flanders Future Tech Fund, KU Leuven, Merieux Equity Partners, Thuja Capital.
AstriVax has raised $35.8M across 3 funding rounds. Most recently, it raised $3.2M Grant in December 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 12, 2023 | $3.2M Grant | Vlaio | — | Announced |
| May 30, 2023 | $2.7M Grant | Vlaio | — | Announced |
| Aug 25, 2022 | $29.9M Seed | Caroline Goddeeris, Shelley Margetson | Ackermans & VAN Haaren, BNP Paribas Fortis Private Equity, Flanders Future Tech Fund, KU Leuven, Merieux Equity Partners, Thuja Capital | Announced |